News | June 28, 2007

Debris Released During Procedure May Harm Kidney Function

June 29, 2007 - Investigators from the Wake Forest University (WFU) School of Medicine in Winston-Salem N.C. and University of California at San Francisco report that debris liberated during angioplasty and stenting of the kidney arteries may harm kidney function.
Matthew Edwards, M.D., lead researcher and vascular and endovascular surgeon at WFU School of Medicine, said blood was collected from kidney arteries immediately after the performance of an angioplasty and stent procedure in 28 patients. The procedures were performed with distal embolic protection using a commercially available temporary balloon occlusion and aspiration catheter system. Details of this research are published in the July Journal of Vascular Surgery. “Blood analysis revealed thousands of particles (average of more than 2,000 per procedure) which were large enough to block the small blood vessels in the kidney,” said Dr. Edwards. “These increasing amounts of debris collected were directly related to worse kidney function following the procedures.”
Angiograms, demographics and laboratory data were reviewed and the filtration rate was estimated before each procedure as well as four to eight weeks post-operative. Significant associations were observed between procedural and anatomic factors, and the amount of captured debris, including renal stent size, preoperative aspirin use, predilation and the ratio of renal artery stent diameter to artery diameter.
“Blockages of the kidney arteries affect up to 3.5 million Americans age 65 years and older and are an increasingly recognized cause of severe high blood pressure and kidney failure,” added Dr. Edwards. “Treating blockages with surgery, or angioplasty and stenting, to try and improve blood pressure control and kidney function as well as subsequent survival while reducing debris particles is essential, so the patient can be free from heart attacks, strokes and dialysis.”
Dr. Edwards added that further investigation is warranted to establish relationships between atheroembolism, end organ functional impairment and clinical responses. “Our results provide unique insight into the complications of renal artery stenting and guidance so we may move forward with important research designed to improve treatments for this increasingly common disease. Embolic protection devices now exist that may prevent the passage of this debris into the kidney and lead to better patient outcomes.”

For more information:

Related Content

Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
Overlay Init